Globus Roe vs Price To Sales Ratio Analysis
GMED Stock | USD 81.78 1.64 1.97% |
Globus Medical financial indicator trend analysis is much more than just examining Globus Medical latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Globus Medical is a good investment. Please check the relationship between Globus Medical Roe and its Price To Sales Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.
Roe vs Price To Sales Ratio
Roe vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Globus Medical Roe account and Price To Sales Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Globus Medical's Roe and Price To Sales Ratio is -0.41. Overlapping area represents the amount of variation of Roe that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Globus Medical, assuming nothing else is changed. The correlation between historical values of Globus Medical's Roe and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Roe of Globus Medical are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Roe i.e., Globus Medical's Roe and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | -0.41 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Roe
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Globus Medical stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Globus Medical sales, a figure that is much harder to manipulate than other Globus Medical multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from Globus Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Globus Medical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.The current year's Selling General Administrative is expected to grow to about 675.6 M, whereas Tax Provision is forecasted to decline to about 34.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 718.9M | 759.1M | 1.0B | 533.4M | Total Revenue | 958.1M | 1.0B | 1.6B | 1.6B |
Globus Medical fundamental ratios Correlations
Click cells to compare fundamentals
Globus Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Globus Medical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 102.0M | 101.0M | 103.6M | 102.6M | 114.6M | 104.1M | |
Total Assets | 1.5B | 1.7B | 2.0B | 2.1B | 5.1B | 5.3B | |
Other Current Liab | 6.7M | 93.4M | 105.1M | 105.5M | 301.5M | 316.6M | |
Total Current Liabilities | 111.4M | 120.8M | 140.2M | 159.2M | 392.3M | 412.0M | |
Total Stockholder Equity | 1.4B | 1.5B | 1.7B | 1.8B | 4.0B | 4.2B | |
Other Liab | 17.1M | 52.4M | 75.7M | 70.5M | 81.1M | 85.2M | |
Property Plant And Equipment Net | 199.8M | 216.9M | 221.1M | 243.7M | 646.9M | 679.2M | |
Current Deferred Revenue | 5.4M | 8.1M | 12.0M | 14.1M | 18.4M | 9.6M | |
Net Debt | (193.2M) | (234.6M) | (188.0M) | (144.5M) | 53.1M | 55.8M | |
Retained Earnings | 1.0B | 1.0B | 1.2B | 1.2B | 1.1B | 764.6M | |
Accounts Payable | 24.6M | 18.2M | 22.0M | 36.1M | 56.7M | 59.5M | |
Cash | 195.7M | 239.4M | 193.1M | 150.5M | 467.3M | 490.7M | |
Non Current Assets Total | 844.6M | 857.7M | 1.1B | 1.1B | 3.2B | 3.3B | |
Non Currrent Assets Other | 21.7M | 32.0M | 36.3M | 43.3M | 78.6M | 82.5M | |
Other Assets | 25.2M | 209.8M | 60.8M | 92.2M | 106.0M | 111.3M | |
Cash And Short Term Investments | 311.5M | 426.7M | 443.4M | 446.1M | 517.8M | 342.9M | |
Net Receivables | 162.4M | 148.1M | 165.7M | 217.3M | 504.9M | 530.1M | |
Liabilities And Stockholders Equity | 1.5B | 1.7B | 2.0B | 2.1B | 5.1B | 5.3B | |
Non Current Liabilities Total | 18.2M | 52.4M | 75.7M | 70.5M | 695.8M | 730.6M | |
Inventory | 196.3M | 229.2M | 237.0M | 299.0M | 848.1M | 890.5M | |
Other Current Assets | 17.2M | 17.8M | 18.4M | 21.0M | 44.6M | 46.8M | |
Other Stockholder Equity | 357.3M | 457.2M | 553.8M | 631.0M | 2.9B | 3.0B | |
Total Liab | 129.6M | 173.2M | 215.9M | 229.8M | 1.1B | 1.1B | |
Property Plant And Equipment Gross | 199.8M | 216.9M | 526.7M | 586.8M | 1.1B | 1.1B | |
Total Current Assets | 687.5M | 821.8M | 864.5M | 983.3M | 1.9B | 2.0B | |
Accumulated Other Comprehensive Income | (2.9M) | 4.0M | (6.8M) | (24.6M) | (10.2M) | (9.7M) | |
Short Term Debt | 74.7M | 88.7M | 94.4M | 2.5M | 12.0M | 11.4M | |
Property Plant Equipment | 202.3M | 216.9M | 221.1M | 243.7M | 280.3M | 146.5M | |
Good Will | 128.8M | 156.7M | 179.7M | 197.5M | 1.4B | 1.5B | |
Intangible Assets | 78.8M | 86.9M | 68.7M | 63.6M | 924.6M | 970.8M | |
Net Tangible Assets | 1.2B | 1.3B | 1.5B | 1.6B | 1.8B | 981.4M | |
Short Term Investments | 115.8M | 187.3M | 250.4M | 295.6M | 50.5M | 48.0M | |
Capital Surpluse | 357.3M | 457.2M | 553.8M | 631.0M | 725.6M | 761.9M | |
Non Current Liabilities Other | 12.2M | 46.2M | 71.4M | 68.8M | 102.9M | 108.1M | |
Long Term Investments | 409.5M | 358.5M | 562.5M | 495.9M | 75.4M | 71.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Globus Medical is a strong investment it is important to analyze Globus Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Globus Medical's future performance. For an informed investment choice regarding Globus Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Globus Medical. If investors know Globus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Globus Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 42.231 | Earnings Share 0.62 | Revenue Per Share 18.217 | Quarterly Revenue Growth 0.631 | Return On Assets 0.0473 |
The market value of Globus Medical is measured differently than its book value, which is the value of Globus that is recorded on the company's balance sheet. Investors also form their own opinion of Globus Medical's value that differs from its market value or its book value, called intrinsic value, which is Globus Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Globus Medical's market value can be influenced by many factors that don't directly affect Globus Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Globus Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Globus Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Globus Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.